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COVID-19 has become major public health problems, with new cases and deaths growing around the world. 
COVID-19 has been reported to associate with a hypercoagulable state, which may lead to venous thromboembo-
lism (VTE) formation. This condition is also associated with worse outcomes in COVID-19 patients. It is, 
therefore, critical for clinicians to identify this condition and manage accordingly. VTE formation in COVID-19 
occurs through several mechanisms, such as inflammatory reaction leading to a hypercoagulable state and 
vascular dysfunction and direct vascular injury by the virus. The rate of VTE formation was as high as 31% in 
Intensive Care Unit (ICU) patients and 9.2% in general wards patients. It was also associated with poor prognosis. 
Thromboprophylaxis with heparin, particularly low molecular weight heparin (LMWH), has been shown to 
improve these patients' prognosis. A careful individual assessment is required to determine which patients will 
benefit from this therapy. There are still no sufficient prospective trials to establish guidelines for VTE thrombo-
prophylaxis in COVID-19. The assessment includes laboratory parameters such as PT, platelet count, D-dimer, 
fibrinogen, and other risk factors incorporated in the PADUA risk assessment model (RAM), versus the risk of 
bleeding incorporated in IMPROVE bleeding RAM.
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 In December 2019, a cluster of acute atypical respiratory 
disease was found in Wuhan, China, followed by rapid spreading from 
Wuhan to other areas. It was later found that a pathogen named severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible 
for this disease. This disease, coronavirus disease 2019 (COVID-19), 
kept growing as the primary health problem worldwide.1,2 As of 20th 
June, this disease has infected 8.148.006 worldwide with total deaths 
of 462.691, while in Indonesia, it has infected 45.029 people with 
2.429 dead cases. 3,4
 
 One of the worse prognostic factors in COVID-19 is hyperco-
agulability state, which can lead to venous thromboembolism (VTE) 
formation. According to Zhai et al., severe coagulation abnormalities 
were found in 20% of COVID patients.  The major coagulation disorder 
was found in almost all patients with the condition of severe 
COVID-19.5 Cui et al. showed that VTE was found in 25% of severe 
COVID-19 patients in ICU, and eventually, 40% of them died.6 
Therefore, clinicians should be able to identify this condition and 
manage it accordingly. In this review, we will discuss the hypercoagula-
bility state and venous thromboembolism (VTE) formation, how to
evaluate the risk of VTE formation in COVID-19 patients, and the role 
of low molecular weight heparin (LMWH) in preventing this condition.
2. COVID-19 Pathophysiology: Its Role on Hypercoagulability    
State and Thromboembolism Formation
 SARS-CoV-2 binds to angiotensin-converting enzyme (ACE) 
2 receptors, which are widely expressed in lung epithelial cells, to enter 
the host cells.3 Three main components for innate immunity in the 
airway; dendritic cells (DCs), alveolar macrophages, and epithelial 
cells, fight against viruses until adaptive immunity is activated. Antigen 
presentation initiates T cell responses via DCs and macrophages.2
 The activated immune cells will produce proinflammatory 
cytokines, including interleukin (IL) 10, IL-6, IL-8, granulocyte-colony 
stimulating factor (G-CSF), tumor necrosis factor (TNF)-α, and macro-
phage inflammatory protein (MIP)-1α.2 These proinflammatory 
cytokines would up-regulate procoagulant factors and down-regulate 
the anticoagulant pathway, particularly protein C. This process will 
result in the activation of coagulation cascade and inhibition of fibrino-
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 Other than through proinflammatory cytokines, it is also 
proposed that SARS-CoV-2 directly injures endothelial cells, as 
endothelial cells also express ACE2.8 The normal endothelium plays a 
significant role in inhibiting thrombosis by producing prostaglandin, 
NO, and ectonucleotidase CD39, which have vasodilatory properties 
and inhibit platelet aggregation.7 Hence, the dysfunction of endothelial 
cells by SARS-CoV-2 will favor thrombosis.
 SARS-CoV-2 antigens can also activate platelets through IL-8 
production. These activated platelets would activate white blood cells 
and form a clot to facilitate the pathogen's elimination.9 Besides, hypox-
ia caused by severe COVID‐19 can cause increased blood viscosity, thus 
stimulating thrombosis.10 Immobilization in COVID-19 patients also 
contributes to increasing VTE events.11
3. Venous Thromboembolism Formation in COVID-19: the 
Incidence and Its Prognostic Significance
 Klok et al. found that the rate of thrombotic complications in 
COVID-19 patients in ICU was 31%, consisting of pulmonary embolism, 
deep vein thrombosis, catheter-related upper extremity thrombosis, 
and ischemic stroke.12 Another study suggested that acute pulmonary 
embolus was found in 23% of patients with severe COVID-19.13  
Furthermore, an autopsy of COVID-19 patients showed microthrombi 
in lung microvasculature, suggesting that refractory hypoxemia in these 
patients might be caused by ventilation-perfusion mismatch due to the 
obstruction of the capillary by these microthrombi. Similar to what 
happens in the condition of severe sepsis, activation of coagulation 
cascade by cytokines can cause disseminated intravascular coagulation 
(DIC), causing multiple organ damage.14 In a study by Tang et al., DIC 
was found in 71.4% of nonsurvivors and 0.6% of survivors during their 
hospital stay.15 Nonsurvivors were found to have a correlation between 
progressive DIC with decreased fibrinogen, increased D-dimer, and 
 
 
increased PT, noting a median count DIC 4 days (1-12 days) after 
admission.16  
 
 Although ICU patients were found to have a higher risk of 
VTE, patients on the general ward were also at increased risk. The 
incidences of VTE in ICU patients were 26% (95% CI, 17‐37), 47% 
(95% CI, 34‐58), and 59% (95% CI, 42‐72) at 7, 14, and 21 days, 
respectively; while for the patients in general wards, the incidences 
were 5.8% (95% CI, 1.4‐15), 9.2% (95% CI, 2.6‐21), and 9.2% (2.6‐21) 
at 7, 14, and 21 days, respectively.17
4. Risk Assessment for Thromboembolism Formation in COVID-19 
Patients
 In COVID-19, the coagulation disorders seem to be similar to 
other coagulopathies due to severe infections, such as DIC and 
sepsis-induced coagulopathy (SIC) SIC, an earlier phase sepsis-associat-
ed DIC, can be assessed using a category by The International Society 
of Thrombosis and Haemostasis (ISTH).10 The SIC scoring system 
includes prothrombin time, platelet count, and SOFA score (Table 1 
and 2). In a study by Tang et al., it was found that severe COVID-19 
patients who meet SIC criteria (≥4) or who have a prominent elevation 
of D-dimer (6 times upper limit of normal) have a better prognosis if 
they were treated with anticoagulant therapy (mainly with LMWH).10 
 Other than the SIC scoring, the predictor of thromboembolic 
formation in COVID-19 is D-dimer, PT, and PTT level. Increased 
D‐dimer levels > 1.5 μg/ml (normal range: 0.0–0.5 μg/ml) can predict 
VTE with sensitivity 85%, specificity 88.5% and negative predictive 
value 94.7%.6 Spontaneous prolongation of the PT by more than 3 s or 








Category Parameter 0 point 1 point 
Prothrombin time PT-INR ≤1.3 >1.2 
Coagulation Platelet count (x109/L) ≥150 <150 
Total SOFA* SOFA four items 0 1 
Table 1. Sepsis-induced coagulopathy (SIC) score27
Note, *The total Sequential Organ Failure Assessment (SOFA) is the sum of the four items (respiratory SOFA, cardiovascular SOFA, hepatic SOFA, 





Cardiovascular SOFA (MAP ± 
vasopressors) 




0 ≥ 400 MAP ≥ 70 mmHg <1.2 <1.2 
+1 < 400 MAP < 70 mmHg 1.2-1.9 1.2-1.9 
+2 < 300 Dopamine ≤ 5 μg/kg/min or dobutamine (any dose) 2.0-5.9 2.0-3.5 
+3 < 200 and mechanically ventilated 
Dopamine > 5 μg/kg/min OR 
epinephrine ≤ 0.1 μg/kg/min 
OR norepinephrine ≤ 0.1 
μg/kg/min 
6.0-11.9 3.5-4.9 
+4 < 100 and mechanically ventilated 
Dopamine > 15 μg/kg/min 
OR epinephrine > 0.1 
μg/kg/min OR 
norepinephrine > 0.1 
μg/kg/min 
>12.0 >5.0 
Table 2. SOFA scoring27
Note, SOFA, Sequential Organ Failure Assessment; MAP, mean arterial pressure
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 A higher score in PADUA risk assessment model (RAM) to 
predict VTE (Table 3) has been associated with worse outcomes in 
COVID-19.18 Its direct relationship with thromboembolism formation 
in COVID-19 has not been studied. 
 Most patients with severe COVID-19 may have other comor-
bidities, such as liver dysfunction, that may increase bleeding risk. The 
predisposing factors of bleeding should be assessed (i.e. using 
IMPROVE bleeding risk assessment model in table 4) and corrected 
actively.
5. Preventing Thromboembolism in COVID-19 Patient: When Do 
We Need It?
 While patients with severe COVID-19 in ICU are at obvious 
increased risk for VTE, those in general wards also have significant risk 
factors, such as immobilization and infectious disease. Considering that 
VTE incidence in non-severe COVID-19 was well above 1% even on 
thromboprophylaxis, anticoagulant thromboprophylaxis has been 
suggested to be given for all admitted COVID-19 patients by the majori-
ty of sources. The ISTH and American Society of Hematology (ASH) 
guideline advised prophylactic LMWH in all COVID-19 patients who 
meet the requirement of hospitalization if no contraindication (active 
bleeding and platelet count < 25 × 109/L).19-21 However, now it is 
required in individual patient's evaluation, integrating VTE risk factors 
and bleeding risk factors with clinical judgment. There were still no 
sufficient prospective trials to establish a guideline for antithrombotic 
treatment strategy in COVID-19 patients. Assessment of VTE risk could 
be done from laboratory parameters such as PT, platelet count, 
D-dimer, and other risk factors incorporated in PADUA risk assessment 
model (RAM), while the risk of bleeding can be assessed using 
IMPROVE bleeding RAM.
6. The Role of Low Molecular Weight Heparin in Thromboembo-
lism Prevention: Mechanism and Administration
 Heparin works by dramatically enhancing the aggregation of 
complexes between antithrombin and coagulation factors such as 
thrombin (IIa), factors Xia, Xa, and IXa, which will disable these coagu-
lation factors. Furthermore, heparin also compromises platelet 
function.7
 Low molecular weight heparin (LMWH) preparations have a 
more significant ability to inhibit factor Xa than inhibit thrombin. It also 
interacts less with platelets than standard heparin, hence lesser 
bleeding side effects and less likely to cause heparin-induced 
thrombocytopenia (HIT). They have higher bioavailability and longer 
plasma half-life, making once-daily administration feasible. LMWH also 
has a more predictable dose-response compared to unfractionated 
heparin (UFH), thus eliminating the need for routine monitoring.7 
Furthermore, LMWH also has anti-inflammatory properties that might 
be beneficial in COVID-19 by significantly lowering the level of IL-6.22 
The reduction of IL-6 level is expected to lessen the cytokine storm 
caused by the virus, thus improving the patient's condition.23 
 
 The current standard dose anticoagulant prophylaxis is 
recommended (table 5), rather than intermediate or full treatment 
dosing.19 The doses of LMWH for prophylaxis are once-daily subcutane-
ous doses of 4000 to 5000 units or twice-daily subcutaneously doses of 
2500 to 3000 units. The dose is reduced in a patient with renal impair-
ment.24 The drug should be administered for at least 7 to 10 days.5 
However, in cases where the patients have a great increase in D-dimers 
and severe inflammation, intermediate or therapeutic dosing should be 
considered, according to the bleeding risk.4 Ranucci et al. found that 
VTE formation still existed with 4000 IU b.i.d LMWH as 
12
Risk Factor Points 
Critically Ill 4 
Inflammatory bowel disease 4 
Active cancer (local or distant metastases and with chemotherapy or radiation in the previous 6 
months) 
3 
Previous VTE 3 
Reduced mobility (bed rest with bathroom privilage for at least 3 days) 3 
Thrombophilic condition (defects of antithrombin, protein C or S, factor V Leiden, G20210A 
prothrombin mutation, or antiphospholipid syndrome) 
3 
Recent trauma / surgery (<1 month) 2 
Age ≥ 70 years 1 
Heart or respiratory failure 1 
Acute myocardial infarction or ischemic stroke 1 
Acute infection or rheumatologic disorder 1 
BMI ≥ 30 1 
Ongoing hormonal treatment 1 
Table 4. IMPROVE bleeding RAM: score ≥ 7 indicates high bleeding risk.29
Note, GFR, glomerular filtration rate; INR, international normalized ratio
Patient population VTE prophylaxis regimens 
Medical patients 
Enoxaparin 40 mg SQ every 24 hours 
(Class I, level B) 
Or 
Heparin 5000 units SQ every 8 to 12 
hours (Class I, level B) 
Renal impairment  
(CrCl < 30 mL/min) 
Not on renal 
replacement therapy 
Enoxaparin 30 mg SQ every 24 hours 
(Class IIa, level B) 
Or 
Heparin 5000 units SQ every 8 to 12 
hours (Class I, level B) 
Extreme obesity patients  
(BMI > 40 kg/M2) 
Enoxaparin 40 mg SQ every 12 hours 
(Class IIa, level B) 
Low body weight 
patients  
(weight < 50 kg) 
Enoxaparin 30 mg SQ every 24 hours 
(Class IIb, level C) 
Or 
Heparin 5000 units SQ every 8 to 12 
hours (Class I, level B) 
Table 5. Standard VTE prophylaxis regimens for patients with high 
VTE risk28
Note, VTE, venous thromboembolism; CrCl, creatinine clearance; BMI, 
body mass index
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thromboprophylaxis in severe COVID-19 infection.  No VTE formation 
was found when the dose of LMWH was increased to 6000 IU b.i.d 
(8000 IU b.i.d if body mass index > 35).25
 In severe COVID-19 patients, it is recommended to use 
mechanical prevention for VTE prevention alternatively to the  contra-
indicated pharmacological thromboprophylaxis due to its high bleeding 
risk or active bleeding. Intermittent pneumatic compression (IPC) and 
graduated compression stockings (GCS) are the mechanical prevention 
that should be given until major bleeding risk factors were removed. 
Once the bleeding risk decrease, the pharmacological thromboprophy-
laxis should be initiated as soon as possible.5
 
 In patients with severe kidney impairment (CrCl <30 
mL/min), The use of unfractionated heparin (UFH) is being recom-
mended.5 Up to date, there was no research evaluating the use of direct 
oral anticoagulant (DOAC) for VTE prevention in COVID-19. However, 
it was known that the use of DOAC in critically ill patients with high 
VTE risk did not reduce the risk of VTE and associated with increased 
major bleeding.26 Another consideration against DOAC use was DOAC 
and COVID-19 medical treatment interaction, (as some of them are 
potent inhibitor of CYP3A4).  The risk of organ failure and the lack of 
an effective reversal agent in some centers also taken as considered 
against DOAC use.20  
7. Conclusion
 Patients with COVID-19 are at increased risk of VTE due to 
several mechanisms; strong inflammatory reaction leading to hyperco-
agulability state, vascular injury due to the direct effect of the virus, and 
inflammatory reaction. Studies have shown that prophylaxis with 
heparin, particularly LMWH, improved the prognosis of these patients. 
A rigorous individual patient assessment incorporating VTE risk factors 
and bleeding risk factors is required. Assessment of VTE risk with 
laboratory parameters such as PT, platelet count, D-dimer, and other 
risk factors incorporated in PADUA RAM, versus the risk of bleeding 
such as incorporated in IMPROVE bleeding RAM, may aid in determin-
ing which patients benefit most with thromboprophylaxis strategy. 
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